TITLE

Management of diabetic retinopathy

AUTHOR(S)
Murphy, Robert P.
PUB. DATE
March 1995
SOURCE
American Family Physician;3/1/1995, Vol. 51 Issue 4, p785
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the treatment for diabetic retinopathy. Risk factors of diabetic retinopathy; Stages of retinopathy; Classification of diabetic retinopathy; Ophthalmologic follow-up examinations for patients with diabetes.
ACCESSION #
9506220138

 

Related Articles

  • Erratum.  // Current Pharmacogenomics & Personalized Medicine;2009, Vol. 7 Issue 4, p303 

    A correction to the article "Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development" that was published in the September 2009 issue is presented.

  • Somatostatin analogue promising for diabetic retinopathy. Cooney, Michael J. // Ophthalmology Times;08/15/98, Vol. 23 Issue 16, p52 

    Reports that octreotide may provide a noninvasive treatment for patients with persistent proliferative diabetic retinopathy after panretinal photocoagulation. Research conducted by B. Luettke and colleagues at from the University of Ulm in Germany; Beneficial effect seen in all...

  • Diabetic retinopathy in Oman: a hospital based study. Khandekar R; Al Lawatii J; Mohammed A J; Al Raisi A // British Journal of Ophthalmology;Sep2003, Vol. 87 Issue 9, p1061 

    The magnitude of diabetic retinopathy, its determinants, and coverage of laser treatment for diabetic retinopathy among registered people with diabetes in Oman are presented. 2249 randomly selected subjects representing 5564 registered diabetics were examined. WHO recommended definitions of...

  • New pharmacologic approaches to treating diabetic retinopathy: An opportunity for pharmacist involvement in patient care.  // American Journal of Health-System Pharmacy;9/1/2007 Supplement, Vol. 64, pS22 

    A quiz concerning new pharmacologic approaches in treating diabetic retinopathy is presented.

  • Acetyl-L-Carnitine (Levacecarnine) in the Treatment of Diabetic Neuropathy: A Long-Term, Randomised, Double-Blind, Placebo-Controlled Study. de Grandis, D.; Minardi, C. // Drugs in R&D;2002, Vol. 3 Issue 4, p223 

    Objective: To assess the efficacy and tolerability of acetyl-L-carnitine (levacecarnine; LAC) versus placebo in the treatment of diabetic neuropathy, mainly by evaluating the effects of treatment on electrophysiological parameters and pain symptoms. Design: This was a multicentre (n = 20),...

  • Erratum to: Comparison of microincision vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy. Yokota, Reiji; Inoue, Makoto; Itoh, Yuji; Rii, Tosho; Hirota, Kazunari; Hirakata, Akito // Japanese Journal of Ophthalmology;Nov2015, Vol. 59 Issue 6, p436 

    A correction to the article "Comparison of microincision vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy" that was published online on September 8, 2015 is presented.

  • Pharmacologic approach suitable for diabetic retinopathy. Charters, Lynda; Campochiaro, Peter // Ophthalmology Times;7/15/2002, Vol. 27 Issue 14, p48 

    Examines pharmacologic treatments that are being evaluated for diabetic retinopathy with the goals of slowing progression of retinopathy, decreasing diabetic macular edema (DME) and treating retinal neovascularization. Information on an oral PKC-beta antagonist; Description of an...

  • Presenter: Treat diabetic retinopathy as inflammatory disease. Hemphill, Nancy // Primary Care Optometry News;Mar2010, Vol. 15 Issue 3, p7 

    The article reports on the presentation given by Clement Trempe at SECO 2010 urging attendees to treat diabetic retinopathy as inflammatory disease.

  • Oral therapy for diabetic complications goes forward. Guttman, Cheryl; Aiello Jr., Lloyd // Ophthalmology Times;10/01/99, Vol. 24 Issue 19, p61 

    Offers a look at the Phase II/III studies launched to investigate LY333531, an oral specific inhibitor of PKC-beta as a therapeutic option for the retinal complications of diabetes. Efficacy of the compound; Role of LY333531 to the resolution of existing macular edema; Preclinical studies;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics